Neoptolemos, J. P., Hackert, T., & Büchler, M. W. (2017). Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial. The lancet, 389(10073), . https://doi.org/10.1016/S0140-6736(16)32409-6
Chicago-Zitierstil (17. Ausg.)Neoptolemos, John P., Thilo Hackert, und Markus W. Büchler. "Comparison of Adjuvant Gemcitabine and Capecitabine with Gemcitabine Monotherapy in Patients with Resected Pancreatic Cancer (ESPAC-4): A Multicentre, Open-label, Randomised, Phase 3 Trial." The Lancet 389, no. 10073 (2017). https://doi.org/10.1016/S0140-6736(16)32409-6.
MLA-Zitierstil (9. Ausg.)Neoptolemos, John P., et al. "Comparison of Adjuvant Gemcitabine and Capecitabine with Gemcitabine Monotherapy in Patients with Resected Pancreatic Cancer (ESPAC-4): A Multicentre, Open-label, Randomised, Phase 3 Trial." The Lancet, vol. 389, no. 10073, 2017, https://doi.org/10.1016/S0140-6736(16)32409-6.